Salmeterol is a long-acting β2 adrenoceptor agonist for inhalation which was introduced last December (Serevent - Allen & Hanburys/ Glaxo). In a preliminary review we concluded that it seemed useful for asthmatics who have symptoms despite conventional treatment including full prophylaxis.1 This article discusses Glaxo’s nationwide surveillance study of salmeterol2 which raises some important issues.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.